{"product_id":"biolegend-108102","title":"Biolegend, 108102, Purified anti-mouse Ly-6A\/E (Sca-1) Antibody, 500μg","description":"\u003cp\u003eLy-6A\/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A\/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA\/2, SJL, SWR, and 129), Ly-6A\/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB\/c, CBA, C3H\/He, DBA\/1, and NZB) have low Ly-6A\/E expression on resting peripheral lymphocytes. The expression of Ly-6A\/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A\/E is thought to be involved in the regulation of both T and B cell responses.\u003cbr\u003e\n500μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: IL-2-dependent mouse T-cell line (CTL-L)\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested WB, IP, IHC - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9. The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP) Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB) Codias EK, et al. 1990. J. Immunol. 144:2197. Malek TR, et al. 1986. J. Exp. Med. 164:709. Codias EK, et al. 1990. J. Immunol. 145:1407. Ivanov V, et al. 1994. J. Immunol. 153:2394. Karlhofer FM, et al. 1991. J. Immunol. 146:3662. Fleming T, et al. 1994. J. Immunol. 153:1955. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC) Umland O, et al. 2007. J. Immunol. 178:4147. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed Pronk CJ, et al. 2011. J. Exp Med. PubMed English A, et al. 2000. J. Immunol. 165:3763. (IHC) Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed\u003cbr\u003e\nProduct Citations: Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed Tremblay M, et al. 2020. Elife. 9: . PubMed Valet C, et al. 2022. J Clin Invest. 132: . PubMed Brassington K, et al. 2022. Front Immunol. 13:1040233. PubMed Weng L, et al. 2016. Sci Rep. 6:38632. PubMed Reeves PM, et al. 2017. Oncotarget. 8:94040. PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Hu X, et al. 2016. Nat Commun. 7:13095. PubMed Paulo E, et al. 2018. Sci Rep. 8:11001. PubMed Chen S, et al. 2022. Cancer Discov. :. PubMed Casey AE, et al. 2018. J Cell Biol. 217:2951. PubMed Inoue D, et al. 2021. Nat Genet. 53:707. PubMed Yoshimi A, et al. 2019. Nature. 574:273. PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed Cardoso F, et al. 2021. Nature. 597:410. PubMed Park JW, et al. 2022. Cancer Med. 11:1925. PubMed Blriot C, et al. 2021. Immunity. :. PubMed Gubin MM, et al. 2018. Cell. 175:1014. PubMed Karmaus PWF, et al. 2019. Nature. 565:101. PubMed Pronk C, et al. 2011. J Exp Med. 208:1563. PubMed Krotenberg Garcia A, et al. 2021. Cell Reports. 36(1):109307. PubMed Oherle K, et al. 2020. Immunity. 275:52. PubMed Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed Samala R, et al. 2013. J Proteomics. 75:5304. PubMed Iida Y, et al. 2020. J Immunother Cancer. 8:. PubMed Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed Silva J, et al. 2022. Nat Commun. 13:4492. PubMed\u003cbr\u003e\nRRID: AB_313338 (BioLegend Cat. No. 108101) AB_313339 (BioLegend Cat. No. 108102)\u003cbr\u003e\nStructure: Ly-6 multigene family, 18 kD\u003cbr\u003e\nDistribution: Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells\u003cbr\u003e\nFunction: Regulates B and T cell responses\u003cbr\u003e\nCell Type: B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells\u003cbr\u003e\nBiology Area: Immunology, Stem Cells\u003cbr\u003e\nAntigen References: 1. Rock KL, et al. 1989. Immunol. Rev. 111:195. 2. Morrison SJ, et al. 1994. Immunity 1:661. 3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697. 4. Malek T, et al. 1986. J. Exp. Med. 164:709.\u003cbr\u003e\nGene ID: 110454\u003cbr\u003e\nUniProt: View information about Ly-6A\/E on UniProt.org\u003cbr\u003e\nClone: D7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Sca-1\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863002042537,"sku":"108102","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-108102","provider":"Iright","version":"1.0","type":"link"}